Clinical Trial Update: Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A completed Phase 1 study evaluated wild-type reovirus in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Wild-Type Reovirus (reovirus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anemia, Recurrent Multiple Myeloma | Phase 1 | Status: COMPLETED